CHIARADONNA, FERDINANDO
 Distribuzione geografica
Continente #
NA - Nord America 9.586
EU - Europa 8.099
AS - Asia 4.936
SA - Sud America 709
Continente sconosciuto - Info sul continente non disponibili 555
AF - Africa 138
OC - Oceania 16
Totale 24.039
Nazione #
US - Stati Uniti d'America 9.116
IT - Italia 2.214
SE - Svezia 2.204
SG - Singapore 1.703
CN - Cina 1.206
DE - Germania 1.050
RU - Federazione Russa 682
VN - Vietnam 572
BR - Brasile 526
HK - Hong Kong 524
CA - Canada 375
PL - Polonia 345
IE - Irlanda 283
GB - Regno Unito 274
FR - Francia 265
IN - India 172
UA - Ucraina 171
FI - Finlandia 150
BD - Bangladesh 132
NL - Olanda 109
KR - Corea 97
TR - Turchia 93
ID - Indonesia 85
AT - Austria 74
AR - Argentina 69
DK - Danimarca 65
JP - Giappone 52
IQ - Iraq 51
ZA - Sudafrica 50
ES - Italia 49
MX - Messico 48
CH - Svizzera 34
BE - Belgio 32
SA - Arabia Saudita 28
EC - Ecuador 26
PH - Filippine 26
PK - Pakistan 25
CO - Colombia 23
IR - Iran 21
UZ - Uzbekistan 21
MA - Marocco 19
CZ - Repubblica Ceca 18
PT - Portogallo 17
VE - Venezuela 16
CL - Cile 15
JO - Giordania 14
PY - Paraguay 13
TN - Tunisia 13
AU - Australia 12
EG - Egitto 12
TW - Taiwan 12
MY - Malesia 11
AE - Emirati Arabi Uniti 10
NP - Nepal 10
DZ - Algeria 9
PE - Perù 9
UY - Uruguay 9
AZ - Azerbaigian 8
HN - Honduras 8
JM - Giamaica 8
LT - Lituania 8
LU - Lussemburgo 8
AL - Albania 7
CR - Costa Rica 7
KE - Kenya 7
KG - Kirghizistan 7
PS - Palestinian Territory 7
ET - Etiopia 6
GR - Grecia 6
HU - Ungheria 6
LB - Libano 6
OM - Oman 6
RO - Romania 6
TH - Thailandia 6
KZ - Kazakistan 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
NI - Nicaragua 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
SY - Repubblica araba siriana 4
BO - Bolivia 3
CI - Costa d'Avorio 3
DO - Repubblica Dominicana 3
EU - Europa 3
GT - Guatemala 3
IL - Israele 3
MN - Mongolia 3
SI - Slovenia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
BH - Bahrain 2
BY - Bielorussia 2
GA - Gabon 2
GE - Georgia 2
HR - Croazia 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
Totale 23.459
Città #
Stockholm 1.882
Ann Arbor 1.229
Singapore 1.021
Ashburn 888
Milan 732
Frankfurt am Main 696
San Jose 694
Woodbridge 501
Hong Kong 493
Fairfield 404
Wilmington 342
Chandler 337
Houston 296
Kraków 280
Dublin 275
Dallas 245
New York 233
Toronto 214
Los Angeles 206
Beijing 205
Council Bluffs 199
Santa Clara 186
Jacksonville 173
Dearborn 167
Seattle 165
Ho Chi Minh City 163
Hefei 159
Cambridge 146
Munich 132
Chicago 129
The Dalles 122
Hanoi 119
Rome 119
Buffalo 88
Seoul 88
Princeton 85
Columbus 82
Helsinki 77
Boardman 70
Lauterbourg 70
Jakarta 66
Nanjing 62
Shanghai 62
São Paulo 60
Moscow 53
Vienna 51
North Kansas City 50
Dong Ket 49
Guangzhou 45
Warsaw 44
San Diego 43
Lawrence 42
Montréal 38
Montreal 37
Turin 37
Atlanta 36
Brooklyn 36
Bologna 35
Tokyo 35
Orem 34
Altamura 32
Cento 32
Chennai 31
Denver 31
Johannesburg 31
Phoenix 31
Brussels 29
Figino 29
Naples 29
Nuremberg 29
Da Nang 28
Lachine 28
London 26
Baghdad 25
Nanchang 25
Brescia 22
Poplar 22
Salt Lake City 22
Tianjin 21
Amsterdam 20
Torino 20
Ankara 19
Zhengzhou 19
Zurich 19
Andover 18
Falls Church 18
Paris 18
Florence 17
Hyderabad 17
Manchester 17
Rio de Janeiro 17
Tashkent 17
Kent 16
San Francisco 16
Boston 15
Dhaka 15
Sacramento 15
Tampa 15
Brusuglio 14
Kunming 14
Totale 15.506
Nome #
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 2.787
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 747
Inhibition of the Hexosamine Biosynthetic Pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 702
Fuzzy modeling and global optimization to predict novel therapeutic targets in cancer cells 548
Design, Synthesis, and Preliminary Biological Evaluation of GlcNAc-6P Analogues for the Modulation of Phosphoacetylglucosamine Mutase 1 (AGM1/PGM3) 513
Protein Kinase A Activation Promotes Cancer Cell Resistance to Glucose Starvation and Anoikis 487
The Nutrient-Sensing Hexosamine Biosynthetic Pathway as the Hub of Cancer Metabolic Rewiring. 482
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation 471
Central metabolism of functionally heterogeneous mesenchymal stromal cells 424
Mitochondria in Focus: Targeting the Cell-Death Mechanism 408
From cancer metabolism to new biomarkers and drug targets 406
Analysis of mitochondrial metabolism in situ: Combining stable isotope labeling with selective permeabilization 395
Transcriptional profiling of immortalized and K-ras-transformed mouse fibroblasts upon PKA stimulation by forskolin in low glucose availability 378
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 376
RAS and PKA pathways in cancer: new insight from transcriptional analysis 375
Cancer cell growth and survival as a system-level property sustained by enhanced glycolysis and mitochondrial metabolic remodeling 356
Suppression of the HBP Function Increases Pancreatic Cancer Cell Sensitivity to a Pan-RAS Inhibitor 356
The Role of Mitochondria in the Chemoresistance of Pancreatic Cancer Cells 354
Expression of transforming K-Ras oncogene affects mitochondrial function and morphology in mouse fibroblasts 343
Ras-dependent carbon metabolism and transformation in mouse fibroblasts 342
Data recovery and integration from public databases uncovers transformation-specific transcriptional downregulation of cAMP-PKA pathway-encoding genes 337
Metabolic reprogramming and dysregulated metabolism: Cause, consequence and/or enabler of environmental carcinogenesis? 335
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: The challenge ahead 324
The Association between Vitamin D and Gut Microbiota: A Systematic Review of Human Studies 323
Energy metabolism characterization of a novel cancer stem cell-like line 3AB-OS 319
Multi-pathway blood biomarkers to target and monitor multidimensional prevention of cognitive and functional decline (nested in the IN-TeMPO study framed within the world-wide FINGERS network) 312
Glucose starvation induces cell death in K-ras-transformed cells by interfering with the hexosamine biosynthesis pathway and activating the unfolded protein response 311
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 308
Integrative transcriptional analysis between human and mouse cancer cells provides a common set of transformation associated genes 302
New Insights into the Connection between Histone Deacetylases, Cell Metabolism, and Cancer 302
Cancer Metabolism as a New Real Target in Tumor Therapy 300
Acquired glucose sensitivity of k-ras transformed fibroblasts 292
Glutamine deprivation induces abortive S-phase rescued by deoxyribonucleotides in K-ras transformed fibroblasts 291
Oncogenic K-ras expression is associated with derangement of the cAMP/PKA pathway and forskolin-reversible alterations of mitochondrial dynamics and respiration 287
Chiral trimethyl lock based on vicinal disubstituent effect: prolonged release of Camptothecin into cancer cells 285
Genetic and Molecular Characterization of The Human Osteosarcoma 3AB-OS Cancer Stem Cell Line: A Possible Model For Studying Osteosarcoma Origin and Stemness 285
Hexosamine Pathway inhibition: one molecule able to induce a Brcaness phenotype as promising cancer therapy 278
PGM3 inhibition Shows cooperative Effects With Erastin inducing Pancreatic cancer cell death via activation of the Unfolded Protein Response 277
Systems biology and the molecular circuits of cancer 277
Towards a systems biology approach to mammalian cell cycle: modeling the entrance into S phase of quiescent fibroblasts after serum stimulation 272
Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer 270
PGC1α/β Expression Predicts Therapeutic Response to Oxidative Phosphorylation Inhibition in Ovarian Cancer 270
PKA stimulation protects K-ras transformed cells from apoptosis induced by glucose depletion reactivating mitochondrial function 265
Mitochondrial Complex I inhibitors and forced oxidative phosphorylation synergize in inducing cancer cell death 265
Mitochondrial Complex I decrease is responsible for bioenergetic dysfunction in K-ras transformed cells 264
Vitamin D supplementation and cancer mortality: Narrative review of observational studies and clinical trials 260
Vitamin D and SARS-CoV2 infection, severity and mortality: A systematic review and meta-analysis 244
Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth 244
PGM3 inhibition shows cooperative effects with Erastin inducing pancreatic cancer cell death via activation of the Unfolded Protein Response 238
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 225
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 220
ALDOC- and ENO2- driven glucose metabolism sustains 3D tumor spheroids growth regardless of nutrient environmental conditions: a multi-omics analysis 218
Itaconate controls its own synthesis via feedback-inhibition of reverse TCA cycle activity at IDH2 217
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 217
Glucose shortage dependent apoptosis in transformed cells upon activation of UPR-autophagy pathway 212
Multicomponent interventions and technologies to reduce the burden of frailty, functional, and cognitive decline: insights from the Age-It Research Program 196
Hexosamine Biosynthetic Pathway inhibition sensitizes pancreatic cancer cells to DNA damage 194
VITAMIN D SUPPLEMENTATION MAY IMPROVE COVID-19 PROGNOSIS? EVIDENCE FROM A SYSTEMATIC REVIEW AND META-ANALYSIS 194
Moving beyond the Tip of the Iceberg: DJ-1 Implications in Cancer Metabolism 187
Targeting the Unfolded Protein Response for Breast and Pancreatic Cancer Therapy 187
PO-259 Inhibition of the hexosamine biosynthetic pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis 179
Targeting the Hexosamine Biosynthetic Pathway with a novel PGM3 inhibitor, FR054, to suppress tumour growth and enhance chemotherapy sensitivity in cancer 178
Inhibition of the Hexosamine Biosynthetic Pathway Enhances Enzalutamide Response in Prostate Cancer Cells 174
PGM3 Inhibition as a Novel Strategy to Induce BRCAness in HR-Proficient Pancreatic Cancer Cells 169
PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect 153
Comparative transcriptional analysis between a K-ras cell model of transformation and the NCI60 human cancer cells collection 151
Hexosamine Biosynthetic Pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 145
High throughput metabolomics analysis in normal and K-Ras transformed murine fibroblasts 120
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 114
Exploiting DNA damage protein O-glycosylation to enhance chemotherapy in pancreatic cancer 114
Exploiting DNA damage response protein O-glycosylation to enhance chemotherapy in pancreatic cancer. 113
Targeting Hexosamine Biosynthetic Pathway to Overcome Resistance in Pancreatic Cancer Treatment 109
Inhibition of HBP by targeting PGM3 enzyme as new anticancer therapy 108
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 100
PGM3 inhibition shows cooperative effects with erastin inducing pancreatic cancer cell death via activation of the unfolded protein response 93
Hexosamine biosynthetic pathway inhibition cooperates with gemcitabine inducing in vitro and in vivo pancreatic cancer regression by enhancing DNA damage 88
Histone glycation: a novel epigenetic target in breast cancer 60
FECH, a novel metabolic target influencing CAR T-cell phenotype and function 17
Totale 24.039
Categoria #
all - tutte 64.058
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.058


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022854 0 0 124 110 87 91 59 43 53 43 101 143
2022/20231.440 157 403 162 156 104 183 11 78 102 6 59 19
2023/2024975 24 38 27 79 100 217 203 44 65 34 23 121
2024/20253.104 176 254 296 141 214 140 255 156 265 447 307 453
2025/202611.137 737 466 768 940 1.139 852 1.225 357 848 2.608 508 689
2026/20271.030 376 455 199 0 0 0 0 0 0 0 0 0
Totale 24.039